Building Anticipation for ISTH 2025 Congress in Washington, D.C.
As the countdown begins for the ISTH 2025 Congress, excitement is palpable among professionals in the thrombosis and hemostasis arena. This prestigious event, organized by the International Society on Thrombosis and Haemostasis (ISTH), is set to attract nearly 5,000 attendees from around the globe.
Scheduled to take place from
June 21-25, 2025, at the Walter E. Washington Convention Center, the Congress is highlighted by the presentation of groundbreaking late-breakthrough abstracts. These innovative findings will emerge from key clinical trials and studies, offering insights that could potentially revolutionize approaches to treatment.
Late-Breakthrough Abstracts: A Sneak Peek
One of the most anticipated sessions of the Congress focuses on late-breakthrough abstracts, which will be highlighted at a dedicated slot on
Sunday, June 22, from
9:30 AM to 10:45 AM in Ballroom A-C. Attendees can expect to hear about various pioneering studies:
- - Comparison of Bleeding Risk: Led by Dr. Lana Castellucci from Ottawa Hospital, this study compares bleeding risks associated with Rivaroxaban versus Apixaban in patients suffering from acute venous thromboembolism.
- - Severe Hemophilia A Study: Dr. Robert Sidonio from Emory University will present findings on a Phase 3 study examining Rurioctocog Alfa Pegol in previously untreated patients with severe Hemophilia A.
- - Alox15 Pathway in Sepsis: Colin Evans from the University of South Carolina will discuss using the Alox15 pathway for treating sepsis-induced lung injury.
- - Safety Study of HMB-002: Dr. Priyanka Raheja from Barts Health NHS Trust will reveal insights from the first-in-human safety and pharmacokinetic study of HMB-002 in patients with Type 1 Von Willebrand disease.
- - Caplacizumab Utilization: Concluding the session, Dr. Paul Coppo from Hôpital Sai in France will detail the potential of Caplacizumab alongside immunosuppression without plasma exchange in thrombotic thrombocytopenic purpura cases.
Full details of these abstracts will remain under embargo until their respective presentation times, ensuring that attendees receive fresh, up-to-date information straight from the researchers.
A World-Class Experience
Dr. Guy Young, Chair of the ISTH 2025 Annual Congress Planning Committee, expressed his enthusiasm for the event, stating, "The ISTH 2025 Congress brings together some of the brightest minds in our field, fostering an environment that will enhance collaboration and innovation. Our scientific program is world-class and promises an enriching experience."
The Congress also features a vibrant industry exhibition. This exhibition is set to showcase the latest in diagnostics, therapeutics, and various solutions that support scientists and healthcare professionals in their quest to improve patient care.
For media professionals keen to cover the event, complimentary press registration is available. More information can be found in the ISTH 2025 Virtual Press Room, and the full details about the Congress can be accessed at
www.isth2025.org.
About ISTH
The International Society on Thrombosis and Haemostasis, established in 1969, is recognized as the leading global medical authority focused on thrombosis and hemostasis. With over 7,000 members from more than 120 countries, ISTH is committed to improving the science and clinical practices related to these critical health issues. Their initiatives include educational programs, clinical guidance, and global awareness campaigns such as World Thrombosis Day on October 13.
As the ISTH 2025 Congress approaches, the anticipation for groundbreaking revelations continues to rise, promising a transformative event for attendees dedicated to advancing the field of thrombosis and hemostasis.